Geriatric Nephrology and Urology

, Volume 5, Issue 1, pp 29–40 | Cite as

Predialysis management of chronic renal failure in the geriatric nephrology patient

  • Maria V. De Vita
  • Narendra Kumar
  • Michael F. Michelis
Review Article


As more people live beyond 65 years of age, it is expected that there will also be more people with advanced renal disease. Since renal failure evolves slowly, awareness of the nature of the alterations involved as well as the principles of conservative management may decrease a patient's rate of progression to end-stage renal disease and dialysis. This review examines the water and electrolyte imbalances of progressive renal failure, systemic disease contributing to renal failure including hypertension, diabetes mellitus, multiple myeloma and amyloidosis, systemic complications of advanced renal disease, nutritional changes and the predialysis management of these disorders.

Key words

predialysis therapy anemia therapy erythropoietin calcium-phosphorus disorders vitamin D therapy hypertension therapy diabetic nephropathy converting enzyme inhibitors elderly nephrology patient 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The sex and age distributions of population in the 1990 revision of the United States global population: Estimates and projections, New York, United Nations 1991.Google Scholar
  2. 2.
    Mignon F, Michel C, Mentre F, Viron B. Worldwide demographics and future trends of the management of renal failure in the elderly. Kidney Intern 1993; 43(41): S18-S26.Google Scholar
  3. 3.
    Ismail N, Hakin RM, Oreopoulos DG, Patrikarea A. Renal replacement therapies in the elderly: Part 1. Hemodialysis and chronic peritoneal dialysis. Am J Kid Dis 1993; 22(6): 759–782.PubMedGoogle Scholar
  4. 4.
    Bergstrom J, Alvestrand A, Bucht H, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrology 1986; 25(1): 1–6.Google Scholar
  5. 5.
    Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. B M S 1988; 297: 1086–1091.Google Scholar
  6. 6.
    Pullman TN, Coe FL. Pathophysiology of chronic renal failure. In Clinical Symposia 1984; 36(3): 3–32.Google Scholar
  7. 7.
    Meyer TW, Anderson SI, Brenner BM. Dietary protein intake and progressive glomerular sclerosis: The role of capillary hypertension and hyperfusion in the progression of renal disease. Ann Int Med 1983; 98: 832–838.PubMedGoogle Scholar
  8. 8.
    Brunskill N and Klahr S. Mechanisms of Progressive Renal Failure. In: Mequid El Nahas A, Mallick NP, Anderson S, editors. Oxford Monographs on Clinical Nephrology: Prevention of Progressive Chronic Renal Disease. Oxford University Press 1993: 1–61.Google Scholar
  9. 9.
    Kumar ND, Michelis MF. Conservative management of chronic renal failure in the geriatric nephrology patient. In: Michelis MF, Davis BB, Preuss HG, editors. Geriatric Nephrology. Field Rich and Associates, Inc. New York, NY 1986: 111–116.Google Scholar
  10. 10.
    Carrie BJ, Golbetz V, Michaels AS. Creatinine: An inadequate filtration marker in glomerular diseases. Am J Med 1980; 69: 177–182.PubMedGoogle Scholar
  11. 11.
    Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–285.PubMedGoogle Scholar
  12. 12.
    Gutman AB, Yu TF. Uric acid nephrolithiasis. Am J Med 1968; 45: 756–779.PubMedGoogle Scholar
  13. 13.
    Steele TH, Rieselbach RE. The contribution of residual nephrons within the chronically diseased kidney to urate homeostasis in man. Am J Med 1967; 43: 876–886.PubMedGoogle Scholar
  14. 14.
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Am J Med 1984; 76: 47–56.Google Scholar
  15. 15.
    Danovich GM, Bourgoignie J, Bricker NS. Reversibility of the ‘Salt-Losing’ tendency of chronic renal failure. N Engl J Med 1977; 296: 14–19.PubMedGoogle Scholar
  16. 16.
    Hollenberg NK, Adams DR, Solomon HS, Rashid A, Abrams HL, Merrill JP. Senescence and the renal vasculature in normal man. Circ Res 1974; XXXIV: 309–316.Google Scholar
  17. 17.
    Macias Nunez JF, Garcia Iglesias C, Bondia Roman A, Rodriguez Commes JL, Corbacho Becerra L, Tabernero Romo JM, De Castro del Pozo S. Renal handling of sodium in old people: A functional study. Age and Ageing 1978; 7: 178–181.PubMedGoogle Scholar
  18. 18.
    van Ypersele De Strihou C. Potassium homeostasis in renal failure. Kid Intern 1977; 11: 491–504.Google Scholar
  19. 19.
    Michelis MF, Murdaugh HV. Selective hypoaldosteronism. Am J Med 1975; 59: 1–5.PubMedGoogle Scholar
  20. 20.
    Levinsky NG. Management of emergencies. VI Hyperkalemia. N Engl J Med 1966; 274: 1076–1077.PubMedGoogle Scholar
  21. 21.
    Eastwood JB, Bordier PH, deWardener HE. Some biochemical, histological, radiological and clinical features of renal osteodystrophy. Kidney Int 1973; 4: 128–140.PubMedGoogle Scholar
  22. 22.
    Bricker NS, Slatopolsky E, Reiss E, Avioli LV. Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 1969; 123: 543–553.PubMedGoogle Scholar
  23. 23.
    Slanina P, French W, Ekstrom LG, Loof L, Slorach S, Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 1986; 32(3): 539–541.PubMedGoogle Scholar
  24. 24.
    Massry SG, Goldstein DA, Malluche HH. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Kidney Int 1980; 18: 409–418.PubMedGoogle Scholar
  25. 25.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136–2143.PubMedGoogle Scholar
  26. 26.
    Chan R, Gleim GW, DeVita MV, Zabetakis PM, Michelis MF. Effects of oral vs. intravenous calcitriol on serum parathyroid hormone levels in chronic hemodialysis patients. Dialysis & Transplantation 1993; 22(12): 736–737.Google Scholar
  27. 27.
    Martin KJ, Ballal S, Domoto D, et al. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 1992; 19(6): 540–545.PubMedGoogle Scholar
  28. 28.
    Coburn JW, Norris KC, Nebeker HG. Osteomalacia and bone disease arising form aluminum. Semin Nephrol 1986; 6(1): 68–89.PubMedGoogle Scholar
  29. 29.
    Ott SM, Maloney NA, Coburn JW, et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 1982; 307: 709–713.PubMedGoogle Scholar
  30. 30.
    Fleming LW, Steward WK, Gell GS, et al. The effect of oral aluminum therapy on plasma aluminum levels in patients with chronic renal failure in an area with low water aluminum. Clin Nephrol 1982; 17: 222–227.PubMedGoogle Scholar
  31. 31.
    U.S. Renal Data System, USRDS 1993 Annual Data Report, The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, Bethesda, MD, March 1993.Google Scholar
  32. 32.
    Ravid M, Savin H, Jutrin I, Bentel T, Katz B, Lishner M. Long-term stabilizing effect of Angiotensin-converting enzyme inhibition on plasma creatinine and proteinuria in normotensive Type II diabetic patients. Ann Intern Med 1993; 118: 577–581.PubMedGoogle Scholar
  33. 33.
    Lewis EJ, Aunsicker LG, Bain R, Rohde R. The effect of angiotensin-converting enzyme inhibition in diabetic nephropathy. N Engl J Med 1993; 329: 456–1462.Google Scholar
  34. 34.
    Hricik DE, Browning PJ, Kopelman R. Captopril-induced functional renal insufficiency in patients with bilateral renalartery stenoses or renal artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373–376.PubMedGoogle Scholar
  35. 35.
    Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Int Med 1991; 115: 513–519.PubMedGoogle Scholar
  36. 36.
    DeVoy MAB, Tomson CRV, Edmunds ME, Feenally J, Walls J. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Int Med 1992; 232: 493–498.Google Scholar
  37. 37.
    Mohammed AS, Yagoob M, Bell GM, ACE inhibitors in diabetic hypertensive patients — a cautionary note. Nephron 1990; 55: 83–84.PubMedGoogle Scholar
  38. 38.
    Bridoux F, Hazzan M, Pallot JL, Fleury D, Lemaitre D, Kleinknecht D, et al. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7: 100–104.PubMedGoogle Scholar
  39. 39.
    Silva FG, Pirani CL, Mesa-Tejada R, et al. The kidney in plasma cell dyscrasias: A review of a clinicopathologic study of 50 patients. In: Fenoglio CE, Wolff M, editors. Progress in Surgical Pathology. Masson N.Y. 1982; 5: 131–176.Google Scholar
  40. 40.
    Kyle RA. Multiple myeloma: Current therapy and a glimpse of the future. Scand J Haematol 1985; 35: 38–47.PubMedGoogle Scholar
  41. 41.
    Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis. Am J Med 1985; 79: 708–716.PubMedGoogle Scholar
  42. 42.
    Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: Colchincine-treated patients compared with cases seen in previous years (1961–1978). Am J Med 1987; 82: 1182–1190.PubMedGoogle Scholar
  43. 43.
    Truong L, Kopelman RG, Williams GS, et al. Temporal arteritis and renal disease. Am J Med 1985; 78: 171–175.PubMedGoogle Scholar
  44. 44.
    Blythe WB. Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 1985; 5: A50–56.PubMedGoogle Scholar
  45. 45.
    Williams PS, Mallick NP. The natural history of chronic renal failure. In: Mequid El Nahas A, Mallick NP, Anderson S, editors. Oxford Monographs on Clinical Nephrology: Prevention of Progressive Chronic Renal Disease. Oxford University Press 1993; 210–258.Google Scholar
  46. 46.
    Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular capillary hypertension stabilizes established glomerular injury. Kidney Int 1987; 31: 752–759.PubMedGoogle Scholar
  47. 47.
    Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intem Med 1993; 153: 1749–1759.Google Scholar
  48. 48.
    Allison MEM, Kennedy AC. Diuretics in chronic renal disease: A study of high dosage furosemide. Clin Sci 1971: 41: 171–187.PubMedGoogle Scholar
  49. 49.
    Cooperman LB, Rubin IL. Toxicity of ethacrynic acid and furosemide. Am Heart J 1973; 85: 831–834.PubMedGoogle Scholar
  50. 50.
    Suki WN, Dawoud F, Eknocyan G, Martinez-Maldonado M. Effects of metolazone on renal function in normal man. J Pharmacol Exp Ther 1972; 180: 6–12.PubMedGoogle Scholar
  51. 51.
    Textor SC, Bravo EL, Fouad FM et al. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73(5): 719–725.PubMedGoogle Scholar
  52. 52.
    Lim VS, DeGowin RL, Zabala D, Kirchner PT, Abels R, Perry P, Fangman J. Recombinant human erythropoietin treatment in predialysis patients. Ann Inter Med 1989; 110: 108–114.Google Scholar
  53. 53.
    Bommer J, Barth HP, Schwabel B. rHuEPO treatment of anemia in uremic patients. Contrib Nephrol 1990; 87: 59–67.PubMedGoogle Scholar
  54. 54.
    Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1988; 2: 97–100.Google Scholar
  55. 55.
    Winerals CG, Oliver DO, Pippard MJ, Reid C, Downn MR, Cotes PM. Effects of human recombinant erythropoietin derived from recombinant DNA in the anemia of patients maintained on chronic hemodialysis. Lancet 1986; 2: 1175–1178.PubMedGoogle Scholar
  56. 56.
    Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990; 88(Suppl 3C): 16S-20S.Google Scholar
  57. 57.
    Sandler DP, Burr FR, Weinberg CR. Non-steroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Int Med 1991; 115: 165–172.PubMedGoogle Scholar
  58. 58.
    Gurwitz JH, Avram J, Ross-Degran D, Lipsitz LA. Non-steroidal anti-inflammatory drug associated azotemia in the very old. JAMA 1990; 264: 471–475.PubMedGoogle Scholar
  59. 59.
    Byrd L, Sherman RL. Radiocontrast-induced acute renal failure: A clinical and pathophysiologic review. Medicine 1979; 58: 270–279.PubMedGoogle Scholar
  60. 60.
    Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction. Kid Int 1992; 41: 1408–1415.Google Scholar
  61. 61.
    Barett B, Parfrey P, Vavasour H, McDonald J, Kent G, Hefferton D, O'Dea F, Stone E, Reddy R, McManamon P. Contrast nephropathy in patients with impaired renal function: High versus low osmolar media. Kid Int 1992; 41: 1274–1279.Google Scholar
  62. 62.
    Rudnick MR, Goldfarb S, Murphy MJ. Mannitol and other prophylactic regimens in contrast media-induced acute renal failure. Coronary Artery Disease 1991; 2(9): 1047–1052.Google Scholar
  63. 63.
    Weinstein JM, Heyman S. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62(4): 413–415.PubMedGoogle Scholar
  64. 64.
    Pfaffle AE, Moses JW, Chan R, Gleim GW, Zabetakis PM, Stugensky K, Michelis MF. Negative fluid balance and the occurrence of radiocontrast associated acute renal failure. Ger Neph and Urol 1994, 4: 71–77.Google Scholar
  65. 65.
    Brenner BM, Meyer TW, Hostetter TH. Dietary protein restriction in the progressive nature of renal disease. N Engl J Med 1982; 307: 652–659.PubMedGoogle Scholar
  66. 66.
    Carella MJ, Gossarin VV, Rovner DR. Early diabetic nephropathy: Emerging treatment options. Arch Intern Med 1994; 154(6): 625–630.PubMedGoogle Scholar
  67. 67.
    Kluthe R, Oechsten D, Quirin H. Six years' experience with a special low-protein diet. In: Kluthe R, Berlyn RG, Burton B, editors. Uremia. Georg Thieme, Stuttgart 1971: 250–256.Google Scholar
  68. 68.
    Giocanetti S. Dietary treatment of chronic renal failure: Why it is not used more frequently. Nephron 1985; 40: 1–12.PubMedGoogle Scholar
  69. 69.
    Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–884.PubMedGoogle Scholar
  70. 70.
    Makoff R. Vitamin supplementation in persons with renal disease. EDTAN ERCA 1992; XVIII(4): 11–14.Google Scholar
  71. 71.
    Blumberg A, Hanck A, Sander G. Vitamin nutrition in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1983; 20(5): 244–250.PubMedGoogle Scholar
  72. 72.
    Ono K, Hisasue Y, Morimatsu M. Should vitamin C supplementation be restricted in regular hemodialysis patients? Trans Am Soc Artif Intern Organs 1986; XXXII: 111–113.Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Maria V. De Vita
    • 1
  • Narendra Kumar
    • 2
  • Michael F. Michelis
    • 1
  1. 1.Nephrology SectionLenox Hill HospitalNew YorkU.S.A.
  2. 2.Nephrology Section, Department of MedicineSt. John's HospitalBrooklynU.S.A.

Personalised recommendations